Esomeprazole magnesium dihydrate

Neuland Laboratories Limited offers a wide range of API's which includes Vilanterol. Therapeutic segment: Bronchodilator . Contact us for more information.

Neuland Laboratories Limited offers a wide range of API's which includes Voxelotor. Therapeutic segment:  Sickle cell disease
 . Contact us for more information.

INTEGRIN LIFE SCIENCES PVT. LTD. offers wide range APIs and Intermediates which includes DOMPERIDONE. Contact us for more information.

INTEGRIN LIFE SCIENCES PVT. LTD. offers wide range APIs and Intermediates which includes Tamsulosin Hydrochloride. Contact us for more information.

INTEGRIN LIFE SCIENCES PVT. LTD. offers wide range APIs and Intermediates which includes Esomeprazole magnesium trihydrate. Contact us for more information.

INTEGRIN LIFE SCIENCES PVT. LTD. offers wide range APIs and Intermediates which includes Lansoprazole. Contact us for more information.

INTEGRIN LIFE SCIENCES PVT. LTD. offers wide range APIs and Intermediates which includes Dexlansoprazole. Contact us for more information.

INTEGRIN LIFE SCIENCES PVT. LTD. offers wide range of Intermediates which includes (1R,2R)-1,2 Bis ( methane sulfonyl-oxy methyl) cyclohexane (Lurasidone Intermediate). Contact us for more information.

INTEGRIN LIFE SCIENCES PVT. LTD. offers wide range of Intermediates which includes (1R,2R)-1,2-Cyclohexane dimethanol (Lurasidone Intermediate). Contact us for more information.

Neuland Laboratories Limited has entered into a development collaboration with LIR Life Sciences Corp to advance a novel transdermal GLP-1/GIP therapy platform for obesity. The partnership highlights Neuland’s growing expertise in peptide development and manufacturing, supporting the development of innovative cell-penetrating peptide (CPP) technologies designed to enable non-invasive drug delivery.

Neuland Laboratories is expanding its process development capabilities with a new $20 million (₹189 crore) dedicated Process Development Centre in Hyderabad. Designed exclusively for process development and integrated scale-up activities, the 135,000 sq. ft. facility will house over 500 scientists and strengthen Neuland’s ability to accelerate development timelines, improve scale-up readiness, and support complex API and peptide programs from early development through commercialization.